advances in the management of cystic fibrosis: a … cystic fibrosis.pdfadvances in the management...
TRANSCRIPT
10/28/2016
1
Advances in the Management of Cystic Fibrosis: A Closer Look at the Roles of CFTR Modulation Therapy
Susanna A McColley, MDAssociate Chief Research OfficerStanley Manne Children’s Research InstituteAnn & Robert H. Lurie Children’s Hospital of ChicagoProfessor of PediatricsNorthwestern University Feinberg School of Medicine
Disclosures
• Consultant: Vertex Pharmaceuticals Inc., Novartis Pharmaceuticals Company, AbbVie Pharmaceuticals
• Funding sources: Cystic Fibrosis Foundation, Cystic Fibrosis Foundation Therapeutics, Inc, NIH, AHRQ
10/28/2016
2
Objectives• Assess newly approved and emerging CFTR-targeted treatment strategies
according to their mechanism of action, efficacy, and safety• Examine the role of CFTR modulation therapy in the treatment and management of
cystic fibrosis• Discuss the importance of genetic testing in suspected adult-onset CF• Analyze optimal strategies to manage and monitor CFTR modulator-related adverse
events in cystic fibrosis patients• Explore strategies to employ a multidisciplinary approach to management of the CF
patient, and communicate effectively with patients and their families about the role of genetic analysis
CF and CFTR
• Autosomal recessive disorder– ~1:4400 births
• >2000 sequence variants; disease liability of most is unclear– 70% of patients worldwide have at least
one copy of F508del– Other pathogenic mutations: 5% or fewer– Updated diagnostic consensus in press
• Multi-organ expression and manifestations– lungs, pancreas, liver, sweat gland, GI
tract, vas deferens, others
• Median survival ~40 yrs in US• Median age of death mid-20s
10/28/2016
3
Pathogenic mechanisms of CF lung disease
Defective CF Gene Product
Defective Ion Transport
Airway Surface Liquid Depletion
Defective Mucociliary Clearance
Obstruction
InflammationInfection
Molecular mechanisms of CFTR dysfunction
CFTR gene
CFTR transcript
ribosome +polypeptide chain
mature CFTR
immature CFTR
Y
nucleus
ER
TGN
endosomalcompartment
plasmamembrane
proteosome
I
II
III IV
V
VI
NMD
Y
Y Y
Y
‘Severe’ ‘Mild’
Most CF patients diagnosed during
adulthood have mild CF mutations
associated with pancreatic sufficiency
10/28/2016
4
7
CF End Stage Bronchiectasis
Between the gene defect and end stage lung disease: “severe” phenotype• Most infants with CF are healthy at birth
– 15-20% rate of meconium ileus• Malnutrition and pulmonary inflammation occur in the first weeks to months after
birth
“Cystic fibrosis is not a disease. It is an inherited predisposition that becomes a disease if it is not treated properly.”
Warren Warwick, MD, around 1990
8
10/28/2016
5
Without pancreatic enzyme replacementtherapy, CF is fatalearly in life• Malnutrition/ vitamin deficiency
related direct mortality• “the nutritional state
deteriorates with advance of the infection”
9
Early growth predicts childhood survival
10
Yen, Quinton and BorowitzJ Pediatrics 2012
10/28/2016
6
The CF lung is nearly normal at birth
Early pulmonary inflammation in CF
• 16 CF infants (mean age 6 months) diagnosed by NBS in Colorado; 11 disease controls (mean age 12 months)
• CF infants with increased markers of inflammation even when cultures negative
12
Khan TZ, Wagener JA et al. Early pulmonary inflammation in infants with cystic fibrosis. AJRCCM 1995; 151:1075-82.
10/28/2016
7
Small airways disease is present during the first months of life in CF infants diagnosed by NBS
Sly, PD et al: American Journal of Respiratory and Critical Care Medicine 2009; 180:146-152
Stoltz DA et al. N Engl J Med 2015;372:351-362
Structural Airway Abnormalities in Cystic Fibrosis
10/28/2016
8
Stoltz DA et al. N Engl J Med 2015;372:351-362
Model of Host-Defense Defects in the Airway of a Person with Cystic Fibrosis
Early pathophysiology of CF: summary and opportunity• Infants with CF are healthy but have severe physiologic abnormalities that must be
treated early to avoid a progressive decline in health• The earliest possible diagnosis followed by disease modifying therapy is essential
to prevent CF lung disease• CFTR modulator therapies may be disease modifying, when given early in life, but
clinical trials are just beginning:– https://clinicaltrials.gov/ct2/show/NCT02797132?term=VX15-809-115&rank=1
16
10/28/2016
9
Between the CFTR gene mutation and lung disease: “mild” phenotype• CF may present in the second, third, fourth or later decade of life with
sinopulmonary disease• Illustrative case: “Ellen”
– Became ill with dyspnea and cough at age 28 during her second pregnancy– Continued to have cough and sputum production after giving birth– Denied significant respiratory symptoms as a child– Spirometry with obstructive defect, FEV1 ~50% predicted– CT scan with bronchiectasis– Sweat chloride values 40 mEq/L– CFTR gene mutation panel: F508del, R117H/7T– In spite of having all recommended pulmonary treatments, FEV1 ~ 40% predicted at age 40
17
Importance of CFTR mutation testing• Aids in diagnosis
– Important for therapy and for monitoring of potential complications – Adults with CF at risk of
• Infertility (men)• Reduced fertility (women)• Recurrent acute pancreatitis • CF related diabetes• Pulmonary complications prevalent in CF (ABPA, mycobacterial infections)
– Increasingly, aids in therapy
18
10/28/2016
10
Gene mutation testing in CF• CFTR mutation panels
– May test from 23 (ACOG panel) to 100s of mutations– Will miss rare mutations, deletions/ duplications– Currently less costly than sequencing
• CFTR gene sequencing– Finds any sequence variant in the CFTR gene
• Still misses deletions/ duplications: need to order separately– Will find disease causing mutations, but also mutations of variable or unknown disease liability– Disease liability of rare mutations is being analyzed in CFTR2: www.cftr2.org
• Essential to have appropriate genetic counseling when testing is performed for any genetic testing– Discuss false negative, identification of mutations of unknown significance– Discuss consequences on family members, notification of possible carrier status– Best done by a certified genetic counselor
19
CF care is multidisciplinary
10/28/2016
11
A nutrient dense, liberal fat diet is associated with increased survival• Survival compared between large CF Centers in Boston and Toronto
(1972-1981)• 10-20 year old patients in Boston were shorter than patients in
Toronto. Toronto males weighed more than Boston males. • Mean forced expiratory volume in one second (FEV1) was not different• Median age of survival: Boston 21 years, Toronto 30 years
– the two curves showed a marked separation from age 10 • The only difference in care was diet: fat restriction in Boston, liberal fat
in Toronto• “The differences in growth and survival in these two patient groups,
with similar age-specific pulmonary function, suggest further examination of nutritional guidance and intervention in CF, especially regarding the traditional restriction of dietary fat.”
– Corey, M. McLaughlin, F J. Williams, M. Levison, H: A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto. Journal of ClinicalEpidemiology. 41(6):583-91, 1988.
Nutrition and pulmonary outcomes are correlated
22“the nutritional state deteriorates with advance of the infection”
10/28/2016
12
US children with CF have a normal BMI
Consistent practice improves BMI in CF children
Multidisciplinary care teams support good nutrition in children and adults with CF• RD: dietary assessment and counseling,
recommendations for supplemental tube feeding
• Nurse: family counseling and support• Social worker: family counseling and
support; referral to resources for food insecure families
• Physician: support of diet, prescription of adequate pancreatic enzymes, diagnosis of comorbidities attributing to poor nutrition
24Savant AP, et al. BMJ Qual Saf2014;23:i81-i89
10/28/2016
13
Population FEV1 is improving
25
…but FEV1 is insensitive to early structural lung disease
Lung Clearance Index
• Multi-breath washout technique assesses:– Gas mixing – Airway patency/ obstruction
• Tidal breating; no effort• Inert tracer gas:
– SF6: wash in and out– N2: wash out with 100% O2
• More diseased airways take longer to wash out
10/28/2016
14
not detected by FEV1n=254 (52.5%)
424038363432302826242220181614121086420-2-4-6-8
FEV1 (SD-S)-16 -14 -12 -10 -8 -6 -4 -2 0 2 4 6 8
Lung Clearance Index
Kraemer R, et al. Am J Respir Crit Care Med. 2005; 171: 371-378.
co-abnormaln=208 (42.9%)
not detected by LCIn=5 (0.5%)
co-normaln=20
(4.1%)
LCI
(SD
-S)
CFF Consensus Guidelinesrh-DNase
inhaled antibiotics
hypertonic saline ibuprofen
azithromycin
Early structurallung damage
Obstruction
Signs/Symptoms
Spirometric loss
Risk factors for disease
Evidence of disease
“Silent” process*
Targeting of Interventions
CFF Guidelines
rh-DNase
inhaled antibiotics
hypertonic saline
ibuprofen
azithromycin
Fix or replace CFTR
Gene therapy
Ion channel agents
CFTR modulators
1. Kirchner KK et al. Am J Respir Crit Care Med. 1996;154:1426-1429. 2. De Jong PA et al. Eur Respir J. 2004;23:93-97; 3. VanDevanter DR et al. Pediatr Pulmonol.2008;43:739-744.
10/28/2016
15
Multidisciplinary care for good pulmonary outcomes• Respiratory and physical therapists
– evaluate posture, teach airway clearance techniques and use of inhalational medications– collaborate with patients and physicians in making treatment decisions on maintenance therapies
• Social workers and psychologists– Screen for depression and anxiety and offer referrals, in accordance with recent practice
guidelines– Refer to programs to offset high medication co-pays
• Nurses– Spend about half their time getting prior authorization for specialty medications!
29
Molecular mechanisms of CFTRdysfunction
CFTR gene
CFTR transcript
ribosome +polypeptide chain
mature CFTR
immature CFTR
Y
nucleus
ER
TGN
endosomalcompartment
plasmamembrane
proteosome
I
II
III IV
V
VI
NMD
Y
Y Y
Y
‘Severe’ ‘Mild’
F508del
G551D and others
R117H
10/28/2016
16
Normal
CFTR Mutations
Defect in CFTR Protein
Reduced Quantity of CFTR at Cell Surface
Reduced Function of CFTR at Cell Surface
CFTR Mutations Reduce the Amount or Function of CFTR at the Cell Surface
Courtesy of Vertex Pharmaceuticals
Class I/II Class III/IV/V
OptimizedPotency and Efficacy
Potentiator HTS
Corrector HTS
VX-770 VX-809
Screened >300,000 Compounds
Synthesized >5,000 Compounds
Approach to Identify and Improve CFTR Potentiators and Correctors
Cell based optical assays using cells expressing F508del-CFTR
Cultured human airway epithelia isolated from CF patients
0
25
50
Non-CF HBE
F508del-HBE
cAMP Agonist
5 min
Chl
orid
e T
rans
port
(A
/cm
2)
Courtesy of Vertex Pharmaceuticals
10/28/2016
17
VX-770 effects in human bronchial epithelial cells
33Van Goor F, Hadida S, Grootenhuis PD et al. PNAS 2009;106:18825-18830.
10/28/2016
18
Ivacaftor phase 3 clinical trial (> 12 years)
35
• FDA approved for G551D mediated CF in 2012• Similar trial results seen in subjects with 8 “non-G551D gating
mutations”; FDA approval for expanded use in 2014• Approved for R117H mediated CF with lung disease in 2015• Label extended to 2-5 year olds • 0-24 month study in progress
Ivacaftor is disease modifying
36
Sawicki GS et al Sustained benefit from ivacaftor demonstrated by combining clinical trial and CF patient registry data. AJRCCM 2015; 192:836-42.
10/28/2016
19
Ellen• Participated in the extension and open label follow-on trials of ivacaftor in CF
patients with the R117H mutation• Improvement in FEV1 and exercise tolerance• Reduced exacerbations• Example of severe “mild” disease and positive effect of a modulator effective for
her specific gene mutation
37
Ivacaftor therapy in CF• Marked efficacy• Well tolerated• Expensive• Indicated for ~6% of the population with CF
38
10/28/2016
20
Nearly half of US CF patients are homozygous for the F508del mutation
39
Using chamber studies of cAMP-stimulated Cl- flux in F508del-HBE (normalized to non-CF HBE)
Vehicle VX-770 VX-809+ VX-770
VX-809
**
*
F50
8del
-CF
TR
Act
ivit
y(%
no
rmal
CF
TR
)
40
0
30
20
10
Cilia
N
Untreated
VX-809
Cell Surface F508del-CFTR
Cytoplasmic CFTR
Functional Additivity of VX-809 and VX-770 in Human Airway Cultures Isolated from F508del CF Patients
Courtesy of Vertex Pharmaceuticals
10/28/2016
21
Combined therapy results age 12+
41
Exacerbation reduction is not predicted by FEV1 improvement
42
McColley SA et al, North American Cystic Fibrosis Conference 2015
10/28/2016
22
Lumacaftor-ivacaftor combination therapy has a disease modifying effect• Similar to ivacaftor, ongoing treatment with lumacaftor-ivacaftor reduces the rate
of lung function decline in F508del homozygotes, compared to untreated F508del homozygotes in the Cystic Fibrosis Foundation patient registry
• These data are being presented at the North American Cystic Fibrosis Conference 10/27/16-10/29/16
• A graph of these data will be displayed at the time of this presentation
43
Lumacaftor-ivacaftor approved for 6-11 year olds• Lumacaftor-ivacaftor recently approved for 6-11 year olds
– Based on open label safety study– Open label study results being presented at the North American CF Conference 10/27-10/29/16– Placebo-controlled study with efficacy measures underway– Additional slides will be displayed at the time of this presentation
44
10/28/2016
23
Monitoring for toxicities and assessing efficacy in individual patients• All patients taking ivacaftor or lumacaftor-ivacaftor should have transaminases
monitored every 3 months for 12 months after initiating therapy• Dose reductions recommended for moderate to severe liver disease (Child-Pugh
Classification)• Children < 12 years old should have an eye exam prior to starting therapy due to
the occurrence of cataracts in exposed rat pups– Ocular safety study has been recently completed, not yet reported
• Chest tightness (“respiration abnormal”) occurs in some patients when initially starting lumacaftor-ivacaftor therapy– Mechanism unknown– Rarely leads to discontinuation of drug
• Monitoring efficacy can be difficult in patients with milder disease– Disease modification and exacerbation reduction benefit
45
Lung disease
Genetic
CFTRmodifiergenes
gender Behavior
exercise smoking
diet
adherence
Therapy
healthcaresystem
CF center
Environment
Luck
infections
socioeconomicspollution
second-hand smoke
nutrition (PI)
siblings
timelydiagnosisexacerbation
rate
CFRD
10/28/2016
24
Summary• Onset of CF lung disease is a post-natal event • Nutritional and pulmonary abnormalities occur very early in life• Lung disease is present even when FEV1 is normal• Genetic testing is important in diagnosis and, increasingly, for therapeutic
considerations• Analyze optimal strategies to manage and monitor CFTR modulator-related adverse
events in cystic fibrosis patients• Multidisciplinary care is essential• CFTR modulation therapy has an increasing role treatment and management of
cystic fibrosis• Modulator therapy may reduce morbidity/ mortality over time
47